Remove tag investing-health
article thumbnail

IBM sells off large parts of Watson Health business

pharmaphorum

A private equity group has agreed to take over most of IBM Watson Health, seven years after the business was launched with a pledge to revolutionise healthcare data analysis. IBM’s step back from health comes as tech rivals are still piling into the sector.

Cerner 111
article thumbnail

Oslo Medicines Initiative asks how to balance innovation incentivisation with security of access

pharmaphorum

And as with many healthcare challenges, it is an issue that has been brought into sharp focus by COVID-19, during which we have seen huge investments in ground-breaking vaccines, quickly followed by inequities in access. Transformative, lifesaving products are available at increasingly high and unsustainable prices.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Orphan drugs and where to launch them: The keys to Europe’s forgotten territories

Pharmaceutical Technology

The commercial investment required to research and develop an innovative drug, prove its safety and efficacy, and bring it to market is staggering. Without a guaranteed return on investment (ROI), it is understandable why any for-profit company would show reluctance. Efforts have been made to change this. Go-to-market strategies.

article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Joanna Carlish, managing director, financial services, Tag Americas. Virtual connections.

article thumbnail

Patient adherence – the key to restoring trust in pharma

pharmaphorum

This lack of trust in such a crucial industry can lead to decreased compliance, poor treatment adherence, and negative health outcomes for patients. Given the high price tags placed on many medications, it’s easy to understand why patients often feel that they are being taken advantage of.

article thumbnail

How to Increase Organic Traffic to Your Pharmacy Website with Google Analytics – BLOG #73

The Social Pharmacist

Companies start generating leads from health services and practices. Unlike those investing in paid search for lead generation, these companies don’t have to pay for clicks. Benefits of Investing in Organic Traffic for Your Pharmacy Business. Benefits of Investing in Organic Traffic for Your Pharmacy Business.

52
article thumbnail

Orphan drugs’ financial success raises questions

pharmaphorum

And of course, in many cases, these drugs have higher than average price tags compared to the wider market which is due to the limited – or in most cases – non-existent competition within a treatment area.”. They added, “Existing incentives and rewards remain essential, as the economic case for investment in these areas is only marginal.”.